Skip to main content
HairCited

Minoxidil pour Alopécie Androgénétique

A

Basé sur 191 études (19 meta-analyses, 21 RCTs) avec 41,495 participants au total. 159/191 études montrent des effets positifs.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dminoxidil\u0026condition\u003Dandrogenetic\u002Dalopecia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

En conclusion

Minoxidil is strongly supported by extensive research as an effective option that may help promote hair regrowth in people with androgenetic alopecia.

  • 191 studies with over 41,000 participants — one of the most researched hair loss ingredients
  • 83% of studies show positive effects on hair regrowth and density
  • Both topical and oral forms are supported by meta-analyses and RCTs
  • Recent expert consensus guidelines support its use as a first-line option

Key Study Findings

review
Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations.
Dose: Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5 vs: Placebo Effet: Comparable efficacy to topical minoxidil; hypertrichosis 24%, shedding 16-22%, peripheral edema 2% None
Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None vs: None Outcome: None Effet: None None

Population: women with androgenetic alopecia (female pattern hair loss)

Other
Low-dose oral minoxidil (LDOM) and topical minoxidil: consensus recommendations for managing male and female pattern …
Dose: MPHL: 1.25-2.5 mg/day; FPHL: 0.625-1.25 mg/day vs: None Outcome: consensus recommendations for managing pattern hair loss Effet: None None

Population: hair transplant patients with male and female pattern hair loss (Delphi panel consensus)

non-randomized controlled trial n=60 16 weeks Open-label
Clinical Efficacy and Mechanisms of Microneedling Alone or Combined With Drugs in the Treatment of …
Dose: Mild group: microneedling alone (8 weeks); Moderate group: microneedling + 5% minoxidil (12 weeks); vs: Placebo Effet: All groups showed significant decrease in HLSS and increase in hair density post-treatment (p<0.001) p<0.001
Case Reports n=1 Open-label
Plica Neuropathica (Polonica) Secondary to Diffuse Alopecia: A Case Report and Literature Review.
Dose: None vs: None Outcome: None Effet: None None

Population: 62-year-old female with diffuse alopecia and plica neuropathica

review
Antiandrogen therapy for the treatment of female pattern hair loss: A clinical review of current …
Dose: varies by agent and study vs: Placebo Effet: variable; oral antiandrogens demonstrate some efficacy; topical antiandrogens possibly fewer systemi None

Key Statistics

299

Études

68291

Participants

Positive

A

Note

Referenced Papers

Journal of the … 2026
Aesthetic plastic surgery 2025 14 citations
Anais brasileiros de … 2025 7 citations
Acta dermato-venereologica 2025 4 citations
European journal of … 2025 3 citations
Australian prescriber 2025 2 citations
Acta dermatovenerologica Alpina, … 2025 2 citations
International journal of … 2025 1 citations
Journal of clinical … 2025 1 citations
Skin appendage disorders 2025 1 citations
Nature reviews. Disease … 2025
Archives of dermatological … 2025
Annals of dermatology 2025
International journal of … 2024 39 citations
Indian journal of … 2024 14 citations
Journal of cosmetic … 2024 11 citations
Journal of clinical … 2024 10 citations
Facial plastic surgery … 2024 8 citations
Photodermatology, photoimmunology & … 2024 8 citations
American family physician 2024 8 citations
Skin health and … 2024 7 citations
International journal of … 2024 5 citations
SAGE open medical … 2024 3 citations
Vestnik oftalmologii 2024 1 citations
Drugs 2023 221 citations
JAAD international 2023 80 citations
Clinical, cosmetic and … 2023 58 citations
American journal of … 2023 41 citations
Anais brasileiros de … 2023 29 citations
Skin appendage disorders 2023 27 citations
Archives of dermatological … 2023 16 citations
Journal der Deutschen … 2023 5 citations
International journal of … 2023 5 citations
Journal of cosmetic … 2023 3 citations
BMJ case reports 2023 2 citations
Clinics in plastic … 2023 1 citations
International journal of … 2023 1 citations
The Journal of … 2022 170 citations
Faculty reviews 2022 44 citations
Dermatology and therapy 2022 43 citations
Dermatologic therapy 2022 41 citations
Journal of cosmetic … 2022 35 citations
Journal of cosmetic … 2022 7 citations
Cureus 2022 3 citations
Facial plastic surgery … 2022
Journal of cutaneous … 2021 44 citations
Journal of the … 2021 42 citations
Actas dermo-sifiliograficas 2021 3 citations
Expert opinion on … 2020 147 citations
American journal of … 2020 127 citations
International journal of … 2020 58 citations
Indian dermatology online … 2020 31 citations
Dermatologic clinics 2020 15 citations
Facial plastic surgery … 2020 15 citations
Alternative therapies in … 2020 11 citations
Drug design, development … 2019 320 citations
Journal of cosmetic … 2019 100 citations
American journal of … 2019 84 citations
Expert opinion on … 2019 34 citations
Bioscience, biotechnology, and … 2019 9 citations
International journal of … 2018 129 citations
Journal of the … 2018 114 citations
Indian journal of … 2018 79 citations
Lasers in medical … 2018 75 citations
Dermatologic therapy 2018 63 citations
Australian journal of … 2018 8 citations
American family physician 2017 141 citations
JAMA dermatology 2017 121 citations
Current clinical pharmacology 2017 62 citations
Actas dermo-sifiliograficas 2017 17 citations
BMJ case reports 2017 6 citations
Deutsches Arzteblatt international 2016 99 citations
The Cochrane database … 2016 18 citations
The Medical clinics … 2015 66 citations
Current problems in … 2015 8 citations
Der Internist 2015
Lasers in surgery … 2014 243 citations
Journal of cutaneous … 2014 168 citations
Expert opinion on … 2014 57 citations
Skin therapy letter 2014 29 citations
Journal of drugs … 2014 26 citations
Giornale italiano di … 2014 8 citations
Giornale italiano di … 2014
Indian journal of … 2013 196 citations
Dermatologic clinics 2013 78 citations
Journal of cosmetic … 2013 62 citations
International journal of … 2013 61 citations
Indian journal of … 2013 16 citations
Facial plastic surgery … 2013 16 citations
International journal of … 2013
The Cochrane database … 2012 15 citations
Expert opinion on … 2010 264 citations
Current opinion in … 2009 54 citations
Seminars in cutaneous … 2009 4 citations
American family physician 2009
Current opinion in … 2008 31 citations
Nihon rinsho. Japanese … 2008 6 citations
Endocrinology and metabolism … 2007 33 citations
Clinical interventions in … 2007
Acta dermatovenerologica Alpina, … 2005
Annual review of … 2004 664 citations
Revue medicale de … 2004
The journal of … 2003 102 citations
Praxis 2003 28 citations
American family physician 2003 2 citations
American family physician 2003
Clinical and experimental … 2002 61 citations
Therapeutische Umschau. Revue … 2002 4 citations
American journal of … 2000 18 citations
Southern medical journal 2000
International journal of … 1999 16 citations
Journal of cutaneous … 1999
Journal of the … 1999
International journal of … 1999
American family physician 1999
Dermatologic clinics 1998 121 citations
Annales de dermatologie … 1997
Journal of the … 1984

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Posologies couramment utilisées

topical:
2-5% solution, twice daily

Limite supérieure : 5% topical solution

Posologies étudiées dans la recherche

Posologie Durée Effet N
Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5 -- Positive --
None -- Neutral --
MPHL: 1.25-2.5 mg/day; FPHL: 0.625-1.25 mg/day -- Positive --
Mild group: microneedling alone (8 weeks); Moderate group: microneedling + 5% minoxidil (12 weeks); 16 weeks Positive 60
None -- Mixed 1
varies by agent and study -- Positive --
None -- Positive --
None -- Mixed --

Moment optimal de prise : Apply to dry scalp morning and evening, at least 4 hours before bed

Safety & Side Effects

Effets indésirables signalés

  • Scalp irritation and dryness
  • Initial shedding phase (first 2-8 weeks)
  • Unwanted facial hair growth (especially in women)
  • Dizziness or lightheadedness (rare with topical use)
  • Heart palpitations (rare, more common with oral form)

Interactions connues

  • Antihypertensive medications (additive blood pressure lowering)
  • Topical corticosteroids (may increase absorption)
  • Retinoids (tretinoin may enhance penetration and side effects)

Apport maximal tolérable : 5% topical solution

Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.

Frequently Asked Questions

Does Minoxidil help with Alopécie Androgénétique?
Based on 299 studies with 68,291 participants, there is strong evidence from multiple clinical trials that Minoxidil may support Alopécie Androgénétique management. Our evidence grade is A (Strong Evidence).
How much Minoxidil should I take for Alopécie Androgénétique?
Studies have used various dosages. A commonly studied range is 2-5% solution, twice daily. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Minoxidil?
Reported side effects may include Scalp irritation and dryness, Initial shedding phase (first 2-8 weeks), Unwanted facial hair growth (especially in women), Dizziness or lightheadedness (rare with topical use). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Minoxidil and Alopécie Androgénétique?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 299 peer-reviewed studies with 68,291 total participants. The overall direction of effect is positive.

Related Evidence

Avertissement FDA: Ces déclarations n'ont pas été évaluées par la Food and Drug Administration. Les produits et informations sur ce site ne sont pas destinés à diagnostiquer, traiter, guérir ou prévenir quelque maladie que ce soit. Les notes de preuve présentées sont basées sur notre analyse de la recherche publiée et évaluée par des pairs et ne constituent pas un avis médical. Consultez toujours votre professionnel de santé avant de commencer tout régime de compléments alimentaires.